(STE) STERIS - Ratings and Ratios
Sterilizers, Disinfectants, Washers, Tables, Services
STE EPS (Earnings per Share)
STE Revenue
Description: STE STERIS October 14, 2025
STERIS plc (NYSE: STE) is a U.S.–based provider of infection-prevention products and services, organized into three operating segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment supplies cleaning chemistries, endoscope reprocessing systems, sterilizers, surgical tables, lights, and related capital-equipment services; the AST segment offers contract sterilization and testing for medical-device and pharmaceutical manufacturers; and the Life Sciences segment manufactures consumables (e.g., detergents, disinfectants, vaporized-hydrogen-peroxide systems) and high-purity water/steam generators, together with installation and maintenance contracts.
In fiscal 2023 STE reported revenue of roughly $4.1 billion, with an adjusted operating margin of about 12 % and free-cash-flow conversion near 15 %. Growth has been driven by two secular trends: (1) rising global demand for infection-control solutions amid heightened awareness of hospital-acquired infections, and (2) expanding outsourcing of sterilization by pharmaceutical and med-device firms seeking to reduce capital-expenditure cycles. The 2022 acquisition of Integrated Healthcare Solutions added endoscope-reprocessing capabilities, which analysts estimate contributed ~3-4 % of FY2023 revenue.
Key macro drivers include aging populations (increasing procedure volumes), tighter regulatory standards for sterility assurance, and supply-chain pressures on high-purity water and steam equipment-factors that can amplify STE’s pricing power but also introduce execution risk. Assuming continued FY-24 revenue growth of 5-6 % and stable margins, the company’s valuation could be sensitive to changes in contract-sterilization demand and capital-equipment replacement cycles.
For a deeper quantitative assessment, the ValueRay platform provides granular cash-flow and valuation models that let you test these assumptions and explore scenario outcomes.
STE Stock Overview
| Market Cap in USD | 23,820m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1992-06-01 |
STE Stock Ratings
| Growth Rating | 76.9% |
| Fundamental | 71.0% |
| Dividend Rating | 58.6% |
| Return 12m vs S&P 500 | 0.59% |
| Analyst Rating | 3.80 of 5 |
STE Dividends
| Dividend Yield 12m | 0.90% |
| Yield on Cost 5y | 1.29% |
| Annual Growth 5y | 9.08% |
| Payout Consistency | 96.9% |
| Payout Ratio | 32.4% |
STE Growth Ratios
| Growth Correlation 3m | -52.9% |
| Growth Correlation 12m | 83.3% |
| Growth Correlation 5y | 59.8% |
| CAGR 5y | 16.70% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.84 |
| CAGR/Mean DD 3y (Pain Ratio) | 2.44 |
| Sharpe Ratio 12m | 0.20 |
| Alpha | -3.12 |
| Beta | 1.026 |
| Volatility | 21.54% |
| Current Volume | 1610.6k |
| Average Volume 20d | 516.9k |
| Stop Loss | 252.2 (-3%) |
| Signal | 0.89 |
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income (646.6m TTM) > 0 and > 6% of Revenue (6% = 334.3m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 2.86pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 20.30% (prev 22.43%; Δ -2.12pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 1.26b > Net Income 646.6m (YES >=105%, WARN >=100%) |
| Net Debt (1.79b) to EBITDA (1.41b) ratio: 1.27 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (98.8m) change vs 12m ago -0.58% (target <= -2.0% for YES) |
| Gross Margin 44.13% (prev 43.13%; Δ 0.99pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 54.32% (prev 48.79%; Δ 5.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 12.88 (EBITDA TTM 1.41b / Interest Expense TTM 71.8m) >= 6 (WARN >= 3) |
Altman Z'' 4.26
| (A) 0.11 = (Total Current Assets 2.06b - Total Current Liabilities 926.6m) / Total Assets 10.40b |
| (B) 0.25 = Retained Earnings (Balance) 2.60b / Total Assets 10.40b |
| (C) 0.09 = EBIT TTM 924.6m / Avg Total Assets 10.26b |
| (D) 2.03 = Book Value of Equity 6.96b / Total Liabilities 3.44b |
| Total Rating: 4.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 71.00
| 1. Piotroski 9.0pt = 4.0 |
| 2. FCF Yield 3.55% = 1.77 |
| 3. FCF Margin 16.31% = 4.08 |
| 4. Debt/Equity 0.30 = 2.46 |
| 5. Debt/Ebitda 1.27 = 1.35 |
| 6. ROIC - WACC (= -0.93)% = -1.17 |
| 7. RoE 9.73% = 0.81 |
| 8. Rev. Trend 59.53% = 4.47 |
| 9. EPS Trend 64.45% = 3.22 |
What is the price of STE shares?
Over the past week, the price has changed by +10.11%, over one month by +8.07%, over three months by +17.87% and over the past year by +15.47%.
Is STERIS a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of STE is around 258.80 USD . This means that STE is currently overvalued and has a potential downside of -0.48%.
Is STE a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the STE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 272.4 | 4.7% |
| Analysts Target Price | 272.4 | 4.7% |
| ValueRay Target Price | 290 | 11.5% |
STE Fundamental Data Overview November 06, 2025
P/E Trailing = 36.2051
P/E Forward = 23.9234
P/S = 4.2756
P/B = 3.4317
P/EG = 1.8407
Beta = 1.026
Revenue TTM = 5.57b USD
EBIT TTM = 924.6m USD
EBITDA TTM = 1.41b USD
Long Term Debt = 1.90b USD (from longTermDebt, last quarter)
Short Term Debt = 35.3m USD (from shortTermDebt, last quarter)
Debt = 2.07b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.79b USD (from netDebt column, last quarter)
Enterprise Value = 25.61b USD (23.82b + Debt 2.07b - CCE 279.7m)
Interest Coverage Ratio = 12.88 (Ebit TTM 924.6m / Interest Expense TTM 71.8m)
FCF Yield = 3.55% (FCF TTM 908.8m / Enterprise Value 25.61b)
FCF Margin = 16.31% (FCF TTM 908.8m / Revenue TTM 5.57b)
Net Margin = 11.61% (Net Income TTM 646.6m / Revenue TTM 5.57b)
Gross Margin = 44.13% ((Revenue TTM 5.57b - Cost of Revenue TTM 3.11b) / Revenue TTM)
Gross Margin QoQ = 45.14% (prev 43.31%)
Tobins Q-Ratio = 2.46 (Enterprise Value 25.61b / Total Assets 10.40b)
Interest Expense / Debt = 0.77% (Interest Expense 15.9m / Debt 2.07b)
Taxrate = 23.24% (53.9m / 231.9m)
NOPAT = 709.7m (EBIT 924.6m * (1 - 23.24%))
Current Ratio = 2.22 (Total Current Assets 2.06b / Total Current Liabilities 926.6m)
Debt / Equity = 0.30 (Debt 2.07b / totalStockholderEquity, last quarter 6.96b)
Debt / EBITDA = 1.27 (Net Debt 1.79b / EBITDA 1.41b)
Debt / FCF = 1.97 (Net Debt 1.79b / FCF TTM 908.8m)
Total Stockholder Equity = 6.64b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.21% (Net Income 646.6m / Total Assets 10.40b)
RoE = 9.73% (Net Income TTM 646.6m / Total Stockholder Equity 6.64b)
RoCE = 10.82% (EBIT 924.6m / Capital Employed (Equity 6.64b + L.T.Debt 1.90b))
RoIC = 8.13% (NOPAT 709.7m / Invested Capital 8.73b)
WACC = 9.06% (E(23.82b)/V(25.89b) * Re(9.80%) + D(2.07b)/V(25.89b) * Rd(0.77%) * (1-Tc(0.23)))
Discount Rate = 9.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.28%
[DCF Debug] Terminal Value 75.95% ; FCFE base≈782.9m ; Y1≈965.8m ; Y5≈1.65b
Fair Price DCF = 209.1 (DCF Value 20.59b / Shares Outstanding 98.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 64.45 | EPS CAGR: 6.07% | SUE: 0.96 | # QB: 2
Revenue Correlation: 59.53 | Revenue CAGR: 5.50% | SUE: 0.27 | # QB: 0
Additional Sources for STE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle